MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Bridgebio Pharma Inc

Open

SectorHealthcare

53.13 1.3

Overview

Share price change

24h

Current

Min

51.8

Max

53.7

Key metrics

By Trading Economics

Income

-16M

-184M

Sales

-6.1M

111M

Profit margin

-166.199

Employees

725

EBITDA

-17M

-143M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+24.35% upside

Dividends

By Dow Jones

Next Earnings

10 lis 2025

Market Stats

By TradingEconomics

Market Cap

866M

9.9B

Previous open

51.83

Previous close

53.13

News Sentiment

By Acuity

82%

18%

352 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Bridgebio Pharma Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 kwi 2025, 09:30 UTC

Top News

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

Peer Comparison

Price change

Bridgebio Pharma Inc Forecast

Price Target

By TipRanks

24.35% upside

12 Months Forecast

Average 66.5 USD  24.35%

High 82 USD

Low 56 USD

Based on 17 Wall Street analysts offering 12 month price targets forBridgebio Pharma Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

17

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

34.71 / 36.9Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

352 / 371 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
help-icon Live chat